Stay updated on Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe revision history is updated to include v3.5.0 as the latest revision and removes v3.4.3.SummaryDifference0.1%

- Check22 days agoChange DetectedThe page revision label was updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

- Check51 days agoChange DetectedThe study status was updated to Completed with actual completion dates, replacing the previous 'Active, not recruiting' status. The page revision was updated to v3.4.2 and the funding-status notice was removed.SummaryDifference0.8%

- Check58 days agoChange DetectedA government funding status notice banner was added and the site revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check65 days agoChange DetectedGlossary toggle added; a new label 'Last Update Submitted that Met QC Criteria' appears and a 'No FEAR Act Data' notice is shown. The site revision is updated from v3.3.4 to v3.4.0.SummaryDifference0.2%

- Check79 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3. This is a minor metadata update with no impact on study details or user-facing content.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.